Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Rating) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 187,000 shares, an increase of 32.8% from the December 31st total of 140,800 shares. Approximately 0.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 73,900 shares, the short-interest ratio is presently 2.5 days.
Hedge Funds Weigh In On Alpha Tau Medical
Large investors have recently bought and sold shares of the stock. ETF Managers Group LLC grew its position in shares of Alpha Tau Medical by 8.2% in the 3rd quarter. ETF Managers Group LLC now owns 96,060 shares of the company's stock worth $561,000 after buying an additional 7,248 shares during the last quarter. Wealthspire Advisors LLC bought a new stake in shares of Alpha Tau Medical in the 3rd quarter worth approximately $132,000. Renaissance Technologies LLC bought a new stake in shares of Alpha Tau Medical in the 3rd quarter worth approximately $111,000. Tower Research Capital LLC TRC bought a new stake in shares of Alpha Tau Medical in the 3rd quarter worth approximately $37,000. Finally, Financial Guidance Group Inc. bought a new stake in shares of Alpha Tau Medical in the 3rd quarter worth approximately $60,000. 1.04% of the stock is owned by hedge funds and other institutional investors.
Get Alpha Tau Medical alerts:Wall Street Analyst Weigh In
Separately, Piper Sandler decreased their price objective on Alpha Tau Medical from $19.00 to $12.00 and set an "overweight" rating on the stock in a report on Wednesday, November 23rd.
Alpha Tau Medical Stock Up 0.8 %
Shares of Alpha Tau Medical stock opened at $4.03 on Monday. The business's 50 day simple moving average is $3.75 and its two-hundred day simple moving average is $5.90. Alpha Tau Medical has a one year low of $3.00 and a one year high of $20.65.Alpha Tau Medical (NASDAQ:DRTS – Get Rating) last announced its quarterly earnings results on Tuesday, November 22nd. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.06. On average, research analysts predict that Alpha Tau Medical will post -0.62 EPS for the current fiscal year.
Alpha Tau Medical Company Profile
(Get Rating)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
See Also
- Get a free copy of the StockNews.com research report on Alpha Tau Medical (DRTS)
- Is Seagate Technology Signaling the End of its Normalization?
- eHealth Stock Rises from the Ashes. Time to Get In?
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.